Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
The latest filing no longer states the doubt (first flagged Aug 10, 2026).
View the 10-Q filed Nov 13, 2026Conference · 2026-11-16
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
I get to say good afternoon. It's 12 o'clock. Thank you very much for being with us here at the UBS Biopharma Conference. I'm Michael Yee, Senior Biotechnology and Pharma Analyst here at UBS, and very excited to have J. Biosciences up here with us. That includes the CEO, Tom Froelich, and President of Research and Development, Dr. Andrew King. Thank you guys for being here. A lot going on in IGAN, and so I would love to turn it over to Tom just briefly. You could give us an introduction to Jade Biosciences. You have a potential best-in-class April inhibitor for the treatment of IGAN. There's a lot of competitors in this space. A lot of people have been listening to Vertex and other companies here, so I'd love for you to give us an introduction to your company and why you think you have a potential best-in-class product in IGAN.
Absolutely, and thanks for hosting us. And other products, too. Yeah, thanks for hosting us and the whole UBS team. It's great to be here in London. Yeah, we're really excited by our entire pipeline at Jade. We're a company developing best-in-class assets across a number of different autoimmune disorders. As Mike pointed out, our lead program is Jade 101, which is a selective anti-April inhibitor. Again, we believe it's a tremendously large commercial opportunity. We believe in the U.S. it's a $20 billion opportunity alone, and we do believe that the selective anti-Aprils are going to be the dominant class because they have the potential to be disease-modifying and have a very good tolerability profile, and then with Jade 101, we think there's a straight line to a best-in-class profile because of the increased potency to capture the full efficacy available to the mechanism, but also the extended... Dosing, which will allow for Q12-week dosing, which for patients who are diagnosed in their 20s and 30s and need lifelong therapy, to be able to control their disease with only four injections a year will be a really big, big advantage. We're currently in a Phase 2 trial, moving very quickly towards a data readout in Q2-2027, so a big, meaningful event for us with 101 next year. But also, we're not waiting for that data. We have so much conviction in this mechanism and the data from our phase one trial that we're aiming to initiate a phase three trial actually this quarter. So moving extremely quickly.
Yeah, I'll repeat that again, initiating plans to start the phase three and the phase two data hasn't been read out.
Yeah, correct. Just because there's so much conviction with that translatability of the healthy volunteer data into what we anticipate to see in patients. So that's 101. Most of the focus of our company is moving that forward, but we're not just a single asset company. We also have J201, which is a BAF receptor program, a really broad B-cell depleter, which we think has TCE-like efficacy in terms of B-cell depletion, but doesn't have some of that baggage associated with the cytokine release syndrome that you do see with TCEs. And we believe with this mechanism, we can apply it to a number of different autoimmune diseases. We're currently in a phase one rheumatoid arthritis study and aim to read out that data next year in 2027. And then at that point, we'll provide more information on how we're planning to progress that trial across a number of different indications as well. Then we have a third program, sorry, to take up a lot of time with the intro here, which is J301, which is targeting interferon beta. That's initially going to be developed in dermatomyositis, which is a very severe neuromuscular and skin disorder, as the name would suggest. We're following the footsteps of a program at Pfizer called Dazu Kaibart, which is also an interferon beta. Showed extremely positive phase 2 data, showing really good activity on the neuromuscular and skin components. So we believe we have a possibility of having a best-in-disease class. And the big liability with Dazukaibar, it has very low bioavailability, so it has to be dosed IV. With Jade 301, the way it's designed, we believe it will be a sub-Q dosing with very convenient dosing as well. So capture all the efficacy for that mechanism, but do it in a much more convenient way for patients. So we're aiming to have data on a health of volunteer study for that program in the second half of next year to enable us to move quickly into patients.
If I could do that in reverse, so people have heard about some of the data that Pfizer has, that Pfizer has moved into a phase three. It's sort of a first-generation drug. It's inconvenient monthly dosing via IV, but the data looks pretty good, and you have a potential much better version of that drug, but pretty de-risked from Pfizer. The second program, 201, I'm going again in reverse, is an anti-BATH. Is this a much better version of the Novartis anti-BATH that has positive Sjogren's data?
That's exactly right. So keeping the same pharmacology as Ionalumab, but the limitation of Ionalumab is it has a very short human half-life of just 10 days, so we've introduced a half-life extension into our molecule to be able to enable better dosing. Is that a YTE? So it's actually not a YTE because we want to have enhanced effector function, and YTE actually kills effector function, so it's actually an LS mutation, which practically has a very similar effect.
Let's say second generation, much better version of the Novartis, which is de-wrist and is approved in Sjogren's or about to be approved? On the cusp, they said this. On the cusp, okay. So that would be good and does have promising efficacy in Sjogren's. So that should be fairly de-wrist. You're noticing a pattern you're de-wrist. And then if we get to the lead program, this is a much higher potency and YT enabled, significantly infrequent, once every six month, three and six month dosing, once every month dosing.
Every 12 weeks.
Every three-month dosing. And the others are dosed monthly. I see my Atsuka analyst in the back there. And so this could be much less dosing in a huge market where people are young, and therefore over decades of use, obviously do not want to be coming in for IV or frequent weekly injections. And by the way, as Jade continues to educate investors about this, I just want to also remind people that you initially started this company after selling Chinook, which was the original April inhibitor, to Novartis. Can you just remind us about that and how this all came together? Yeah, that's great. Because you have experience in this field.
Yeah, so Andrew and I have worked in IGAN and together for a long time. I was one of the founders of Chinook in 2019, and then Andrew joined very early on and helped with the whole pipeline build. And we've had a long-held conviction around IGAN that it's going to be, A, a big market, B, that disease-modifying APRIL inhibitors are going to be really the foundational therapy for patients, and that there was still room, even though there was a number of different assets in place. So that's why Andrew came across the Paragon team, worked with them to develop and design 101, and we launched the company a couple years ago.
Right. Okay. So let's talk a little bit about Jade 101. So coming back now to the main program, Jade 101 is a YT-enabled compound that came out of Paragon Labs, and most people here are familiar with Paragon through Apogee and Aruca and a lot of successful stories. as you were following in that and applying that to an anti-April. Can you walk through the key phase one data that was, you know, reported fairly recently and why you have confidence that that phase one data would lead to potential best-in-class profile, and this data is coming in, you said, Q2. So is it going to be better than Atsuka and Vera and Vertex per denariate?
Yeah, we're really encouraged by that first in human healthy volunteer study because it's so biomarker rich and so ultimately predictive of the clinical benefit that you see in IGAM patients. In particular, it's the depth and duration of IgA reductions that are shown to predict proteinuria benefit at nine months of treatment. And what we saw with Jade 101, particularly focusing on the 700 milligram dose, the induction dose we're taking forward, is very rapid and very deep IgA reductions that exceeded those that have been observed previously with the first generation agents and healthy volunteers. And they were sustained for 12 weeks, which gives us confidence that we can deliver the full. Therapeutic benefit of the disease-modifying action on B-cell modulation with a quarterly dose, and that's what gave us conviction to move quickly into phase three, not waiting for that phase two data to read out because the healthy volunteer PKBT with anti-April's has been shown to be highly consistent of what you see in IGAM patients. Yes.
So IgA is a fairly validated marker for the B cells. So again, can you quantify that data? So you showed what amount and then what have the first generation approved drugs shown?
Yeah, the first-generation agents seem to have a maximal IgA reduction in healthy volunteers of 50% to 55%. With Jade 101, again, at that 700 milligram induction dose, which we think is reflective of steady-state responses with repeat dosing in IGAM patients, we saw IgA reductions approaching 70%, so quantitatively larger and faster.
Is that mean, median, all of them showed that? I can't remember the exact number.
That was the mean reduction. What was also a characteristic of our data set was very low individual patient variability, which we think is reflective of the potency of Jade 101 to just completely suppress APRIL and drive IGA reductions to the maximum biological effect. And that was observed more rapidly than those first-generation agents. So we do think in IGAM patients, there is potential for this rapid and deep IgA reduction to translate to better and earlier reductions in proteinuria than the first-generation agents, and maybe more importantly, increase the number of participants that achieve those clinical remission-type endpoints on proteinuria that are highlighted in the KDGO guidelines.
Yeah, so if I were to take a step back before we get into some of what this means, to be fair, initially a lot of folks would just view this as a significantly more convenient option. So less frequently administered in a huge $20 billion type TAM. Just to be fair, we've got multiple people that cover all the different molecules. Vertex was just here. I don't think there's any huge debate that each one of these can do a couple billion dollars and that you have a potential less frequently. But you do believe that it's not just the less frequent dosing, which is important because these people have been born for decades, but you do believe the efficacy because of a more potent antibody will actually drive higher reductions in proteinuria and therefore potentially better EGFR. Is that true?
So, the first generation of agents have actually showed EGFR stabilization, which is truly remarkable. The first time we've ever seen a disease-modifying therapy in nephrology. EGFR loss in IGAN, along with other chronic kidney diseases, is thought to be a result of nephron loss, and those nephrons are not regenerate. You can't regenerate those nephrons. So, EGFR stabilization is the best you can hope to achieve. So over a one to two year phase three clinical trial, we don't anticipate to do better than cibuprenlimab, for example, which showed a numeric increase in EGFR over baseline. But it's important to recognize that two years is a relatively short duration of a 20 or 30 year old IGAM patient's ultimate trajectory. And it's important to stabilize EGFR for decades to prevent the consequences of end-stage kidney disease requiring dialysis or transplantation. What we do know from the epidemiology of IGAN is it's residual proteinuria that's the strongest predictor of long-term clinical outcomes over decades. So although we don't think there's the potential to differentiate in a one- or two-year clinical trial on that EGFR, we do think ultimately the depth of proteinuria reduction is going to be a really important differentiator. Nephrologists really treat from visit to visit on proteinuria changes. It takes time for EGFR trajectory to show itself, and EGFR varies significantly from visit to visit. And the KDGO guidelines are really focused on delivering patients' proteinuria levels back to within the normal range because we know that gives us the highest confidence that their long-term trajectories and outcomes will be beneficial.
So you, again, ultimately, these are driven by longer-term outcomes. But taking a choice of giving one of the drugs, you do believe that your pertinent reductions would come in on the higher end or a little bit numerically better than others. Call it 50%. And change. And others are a little bit lower than that. And that ultimately, not only would you see that, but perhaps more people would get to that certain level because there's greater potency so that on a responder rate basis, more people are achieving that, not just the average is 50 percent. Follow me. And then third, that perhaps the other drugs, more regular dosing, that could lead to dropouts or skipping doses on the margin over 20 years. Again, there's people that are missing, so they're not going to get the optimal outcome, or that there's anti-drug antibodies and neutralizing antibodies in some cases from others that could impact that. Now, Atsuka would make the claim otherwise, but that ultimately over 10 years could be a factor. And so you think that from an efficacy perspective, you would have the best and from a less frequent dosing.
Okay, exactly.
So then if you have this 70% reduction in IgA and others are like 50%, you believe that your pertinence reduction in Q2, can you tell me about how many patients, what time period, And we're just going to get this press release with pertinence reductions, and Wall Street should kind of compare it to others and say, where do you stand versus others? And that, you know, I won't say 51, 50, 49. But whatever the number is, tell me what you think you're going to get. And you think that's going to be the best efficacy out there? What do you think?
Yeah, so the phase two study is a relatively small open-label trial with 15 participants in each cohort. So we don't want to anchor quantitatively too much on a single expectation on proteinuria because of the biologic variability in proteinuria and the small sample size. Our goal is to really deliver that full disease-modifying benefit in IGAM patients. So that would be these deep IgA, GDIGA1 reductions, these 50%-ish reductions in proteinuria that we're seeing with the first-generation agents, high rates of hematuria resolution, but with a Q12-week dosing interval. We think that full therapeutic benefit with that Q12-week dosing interval would be a highly differentiated result.
Yeah, so just to be clear, sure, we'll look at the number. You think that it should be very competitive with a 50%-like number. I won't pin you an exact number, but again, the trial design was one induction dose. Not three doses like everybody else. One induction dose, correct? And then you measure it at 12 weeks. Is that kind of the right design?
So it's going to be an induction dose, 700 mgs, so that's two injections, and then we start maintenance dosing at week four with a single injection. And then every eight or 12 weeks. So there's two dose arms. So we will be looking at some extended follow-up after MAD. Um, and we do aim to have that, um, in Q2 next year. Um, you know, ERA is, is possibly a target, although we need to see if that's submitted there, um, and, and accepted. Um, but we started dosing that trial in, in May of this year. So you can imagine we'll have some patients out, you know, nine months plus follow-up, like a handful of patients and then a lot more at earlier time points. And so we should be able to see, you know, how are we doing with the two 12 weeks of dosing? And are we hitting those numbers that you talked about? And that'll give us like exceptional confidence that we're on track for a phase three readout.
Now, again, I think there's some scenarios about where you're here, here, here, but generally speaking, you have very high confidence, as do we, that it will come right in line with what you sort of think and be very competitive to others, and again, the frequency of dosing is a key longer-term competitive advantage, but that you have confidence it should be positive. Ultimately, that is to support the phase three, which you just said you're going to be already starting, because a lot of people would say, yeah, but Vertex is about to be approved this month. Atsuka, they're already on the market. They're pretty good drugs. We asked doctors, they're pretty good drugs. And you haven't started phase three yet, but you're not that far behind. So for investors looking at this, it's not like you're putting up phase one data. So what is the timeline around that? And would you say you're kind of like two years behind others, And that's not that big of a deal. And so tell us about this timeline, because it is unique that you're starting phase three already.
Yeah, it's probably a little early to provide exact guidance, but we are on track to initiate the trial this quarter. So moving really quickly. You think about other IGAN trials, phase three trials have taken kind of 15 months to 24 months to recruit. We need to do a little bit more, see that initial run rate, but, you know, you could probably see somewhere in that ballpark is where we would...
You said how many, 15 months?
Yeah, the average trial was about 24 months to recruit, so those were the first-generation ones. Actually, we looked at our Vertex colleagues and see they did an exceptional job. They recruited 600 patients in 15 months, so that's kind of like the high-water benchmark to look at. Obviously, they had Vertex dollars and resources to pour into that. You got vertex dollars. Almost. Well, maybe with your help at some point.
You've got some good balance sheets.
But yeah, but you can look at somewhere in between those two is probably a safe projection to think about our recruitment. And then what's really exciting is we believe a 12-month endpoint is suitable for full approval. There was a meeting that was really convened by the National Kidney Foundation, but involved industry, some KOLs, patient groups, and most importantly, the FDA. And that was a meeting, a workshop that happened in April of this year. And they're looking at what does a trial design look like in this contemporary setting with these new agents and really realizing that a two-year... End point with a two-year placebo period is not suitable for patients anymore. It's not ethical to allow them to placebo.
Yeah, it has to do with the two-year placebo factor.
And also just feasibility of recruiting. Nobody wants to stay on placebo for two years anymore. So that workshop really convened around a 12-month end point for full approval. So 15 plus 12, give or take. Well, 15 on the aggressive side.
15 on the aggressive side. Well, 15 to 24 plus the 12-month end point. Right. And to what degree do you think, just again, think from an execution standpoint over the next 12 plus months, that that's mostly a U.S. enrollment? There are drugs available out here. How much is that taken into consideration? Because, you know, again, blocking and tackling is important. So you're like, oh, should we just go out and enroll here in the U.S.? I don't recall if the other three studies were like 50-50 or how they enrolled. I don't remember the breakdown. Do you need to kind of go more OUS to get these patients?
Yeah, historically, most of these trials have been OUS, and typically about 15%, so 1.5% of patients have come from the U.S. Why is that? That seems low, actually. So it's just been historically a very difficult place to recruit comparatively, and we're taking a very similar strategy. You want to talk about our recruitment strategy for phase three?
Yeah, IGAN is a global disease. The prevalence epidemiologically is higher in Asian regions. These typical phase 3 IGAN trials are around 400 to 500 patients, typically in 30 to 35 countries around the world. 55 to 60 percent of it comes from Asia, actually, consistent with their epidemiology. And as Tom mentioned, a relatively small proportion within the U.S. We actually saw with the Atacacept integrated review recently publicly available, They had a fairly limited sample size from the U.S., even in a first-generation anti-April program. And to address this, the FDA pulled data from additional U.S.-like countries, which included Canada, the U.K., Belgium, Greece, and Australia, to get an understanding of a broader patient population that's U.S.-like. So we do think mostly there'll be tailwinds for us to enroll this study. These agents are not approved outside of the U.S., where most of the enrollment comes from, such that entering a Jade 101 Phase III program is the only way to get access to a disease-modifying B-cell modulator. We do recognize that within the U.S., based on the approvals that you've mentioned, it will be a little more challenging. Right. Although right now we estimate less than 3,000 patients in the U.S. are on B-cell modulators out of the 170,000 confirmed diagnosed IGAM patients.
Okay, so I didn't appreciate that, but that's something that Jade will execute on, is going outside the U.S. to do this. That's not uncommon, and including a little bit in Asian countries, I guess, would be part of it. So we talked about other first-generation products and how you think they're differentiated. There are some long-acting April, and there's a long-acting April BAF. I think that's, like, preclinical. To what degree do you think that these, which are also... A year or whatever the difference is behind, do those products compete with you?
So first of all, we think...
One's a degrader, just to be careful. I mean, we're just opening. Climb is one of those.
Yeah, Climb is one of those. And then I think you mentioned like a preclimb, like Boulevard Bio is doing April Bath. We do think that... That this is a large market size, and the emergence of these other therapies really is pointing to the fact that convenience in a 12-week dose is going to actually dominate the market. That will be the game. That will be the benchmark, so we recognize that, and that will help. We still have very strong conviction, though, that we have the best-in-class asset. None of the other agents have the potency of Jade 101 that Andrew nicely described, so we're 2,000-fold more potent than Zygachibart, which is likely similar to the potency of the Climb molecule. So we are aiming with Jade 101 to get these deep, profound early reductions in IgA, which we think will translate into potency and efficacy advantages. And then with the April BAF inhibitors that are coming behind, you know, we've had this long-held conviction that BAF is not contributing to clinical activity in IGAN, and that April is really the core driving the pathophysiology. So we believe we can positively differentiate there, too. So we believe we have the best in class, best in disease long-acting.
Yeah, like, so in thinking about April Baff, April Baff from Vertex, yeah, that's nice that they're hitting Baff, but the clinical efficacy is not hugely differentiated, although it's a nice monthly auto pen injection, but could raise hypothetical, I definitely say hypothetical concerns about safety, so there's no real advantage in adding Baff, is your point, and plus Boulevard is fairly behind. Okay, so we look forward to that Q2 data. You said that we'll put out some of that pertin area data. You think it could be, you know, very competitive with the high-end molecules and very infrequent dosing, and the phase three plans are getting underway. Okay, if I could quickly run through Program 213, just in the interest of time, I have not been very familiar with 201. I would just say that 301 and dermomyositis is more interesting because Pfizer and Ray Vant and some of these others, but just really quickly on 201 because there's data coming. This is a BAF, and the point is that people doing work in Sjogren's are now familiar that Novartis has positive Sjogren's data with the BAF, and that product is about to be approved imminently. Um, there in Sjogren's, you're an RA. Is your program much more efficacious than theirs? And what would you show an RA, not because you are going to go an RA or that that's just a proof of concept? I would say, you know, can you clarify that for me?
Yeah. So, so we're treating that, that first in human study in rheumatoid arthritis, almost like a healthy volunteer surrogate.
Okay.
Uh, we, we didn't feel it was appropriate to go into healthy volunteers with this mechanism. So you want to go into an active disease population. And in the autoimmune setting, RA is the fastest to recruit. So we're treating that more like a healthy volunteer study where we're looking at very typical elements of safety, PK, PD. And what we expect to see there is really to look at what are the B-cell depletion dynamics that we're getting, and also looking very closely at receptor occupancy levels. Um, because if we do look at the ionalumab data, um, they studied two different dose frequencies, a Q4 week dose and a Q12 week dose. And we believe they modeled the Q12 week dose just looking around the PD effects of B cell depletion. But then the Q4 dose was more around the timing of, of, of receptor occupancy. And that's important with this mechanism because we're blocking BAF receptor. So you do get that rapid B-cell depletion through ADCC, but then also BAF is a pro-stimulatory, pro-survival signals. What happens when you get rapid elimination of B-cells, you get an upregulation of BAF. So you want to block that receptor as long as possible to stop that repopulation and actually limit the tissue-specific depletion. So what we'll be looking for is really what is that length of receptor occupancy, and that will drive our dose frequency.
So that is the PD marker. Correct. However long it is completely, I guess, inhibited would be the effect, and therefore that could be longer acting. And better than the Novartis compound.
So what we expect to have is a longer dosing frequency, but then also with that more complete inhibition of the receptor, we could potentially get to better levels of clinical activity as well.
Would the primary lead indication of your go-to phase two in show runs, or would it be in something else?
So we're still determining that. We're looking at a number of different indications that Novartis is in, but also for strategic and pipeline prioritization reasons. There's a number of smaller, more niche indications that they haven't gone into as well. So we'll disclose more on that next year.
And then lastly, in the last minute, 301 in dermomyositis, you put out some interesting data recently. You had a webcast on it. Again, people are somewhat familiar with this indication through the work of Roy Vant. And also Pfizer has it in Phase 3. I cover Pfizer, positive or not. They have been in Phase 3, but they are taking a long time enrolling. I don't know if that speaks to a small market or maybe it speaks to prioritization. But just really quickly, what was the data that you showed and what is the next step for 301?
Yeah, we showed a really differentiated profile pre-clinically from Pfizer's Dazukaibar, which demonstrated very strong clinical proof of concept, both on the muscle and skin components of dermatomyositis. J301 is a fully human monoclonal antibody. It's about three to five-fold more potent at binding and blocking interferon beta than Dazukaibar. It's been engineered with the YTE half-life extension for decreased human clearance and an extended dosing interval. The most important limitation of Pfizer's first-generation agent is it has low subcutaneous bioavailability in the 40% range. And as a result, it requires high IV frequent doses every month. Jade 301 has been selected for improved sub-q bioavailability. So we think differentiating, delivering that disease-modifying benefit that Pfizer did with Dazukaibot with a subcutaneous infrequent dosing schedule would be a very differentiated profile.
And so where are you in terms of the next step? Because you just put up this phase one data.
Rapidly marching towards a first in human healthy volunteer study, which we plan to report out in the second half of next year.
Perfect. All right. So plenty of things across all three of those programs. Thank you for those updates. Look forward to these data readouts coming soon and more execution in 27. So thank you very much, guys.
Thank you. Yeah, we've got a big year next year with three readouts across all our programs. So it's going to be really meaningful.
Thank you, guys.
0:00 to 30:18 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
I get to say good afternoon. It's 12 o'clock. Thank you very much for being with us here at the UBS Biopharma Conference. I'm Michael Yee, Senior Biotechnology and Pharma Analyst here at UBS, and very excited to have J. Biosciences up here with us. That includes the CEO, Tom Froelich, and President of Research and…
Tom Froelich: Absolutely, and thanks for hosting us. And other products, too. Yeah, thanks for hosting us and the whole UBS team. It's great to be here in London. Yeah, we're really excited by our entire pipeline at Jade. We're a company developing best-in-class assets…
Also speaking: Andrew King